JWH-366

JWH-366 is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the Cannabinoid [receptor 1|CB₁] and CB₂ receptors, with a strong selectivity for the CB₂ receptor over the CB₁ receptor. JWH-366 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB₁ receptor.

Legality

In the United States JWH-366 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-366.
In Canada, JWH-366 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.
In the United Kingdom, JWH-366 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.